Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Oct 24, 2023
Kazia announces Clinical Data at ESMO 2023 from EVT801 Study
Oct 23, 2023
Change in substantial holding
Oct 16, 2023
Change of AGM date
Oct 13, 2023
Shareholder communication on the ASX de-listing process
Oct 11, 2023
Kazia announces intention to voluntarily de-list from ASX
Oct 11, 2023
Reinstatement to Official Quotation
Oct 10, 2023
Voluntary Suspension
Oct 6, 2023
Trading Halt
Oct 5, 2023
Presentations at upcoming scientific meetings
Sep 29, 2023
Acceptance of late-breaking abstract of PNOC022 data
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement